The present invention relates to a transvesicular drainage device designed to drain excessive fluid from a bodily cavity into the bladder. More particularly, the present invention relates to a vesicular drainage device that may be coupled to the bladder's wall and control flow of excess fluid from a region of the body into the bladder.
In medicine there are a variety of conditions which result in pathologic chronic collection of bodily fluids. Chronic pericardial effusions, normopressure hydrocephalus, hydrocephalus, chronic pulmonary effusion, and ascites are but a few of the conditions in which chronic fluid collections persist and result in increased morbidity and mortality. These conditions currently are treated by different methods, more particularly: (1) external drainage with a high-risk of infection and long-term requirement for multiple punctures, (2) drainage to another body-cavity, or (3) various drugs.
For pericardial effusions and hydrocephalus of all types, the treatment of choice is drainage to another region of the body. This treatment entails a pericardial window, a highly invasive procedure in which a large section of the external heart cavity is removed. For hydrocephalus, the treatment of choice typically involves the use of a ventriculo-peritoneal shunt draining the cerebrospinal fluid into the peritoneal cavity. Unfortunately, this device frequently becomes clogged due to the proteinaceous environment of the peritoneal cavity and requires removal or revision.
More particularly, ascites is a highly debilitating complication associated with many medical conditions including liver failure and congestive heart failure. Untreated ascites can result in respiratory compromise, compression of the inferior vena cava (a vital blood vessel) and spontaneous bacterial peritonitis (a life-threatening condition). In order to treat chronic ascites, medicine has turned to both drugs and surgery.
The drugs required to treat ascites are typically long-term and frequently result in complications. The most common pharmaceutical treatment of ascites involves the use of diuretics to remove fluid from patient's body through their urine. The difficulty with this treatment is that fluid is removed from the entire body, including the circulating volume of blood, and can result in excessive loss of fluid required to perfuse the vital organs of the human body. Thus, even with religious application, drug treatments frequently fail and surgical, or invasive, procedures become necessary.
The current treatment of choice is called paracentesis. In paracentesis, the peritoneal fluid is drained through the abdominal wall via the insertion of a needle through the abdominal wall into the peritoneal cavity. Unfortunately, this procedure is only a temporary fix as the ascites quickly refills the peritoneal cavity in most chronic conditions. Furthermore, repeated paracenteses put the patient at increased risk for a life-threatening infection of their peritoneal cavity. Other surgical/invasive procedures involve treatment of the cause of the ascites (for example the Transjugular Intrahepatic Portosystemic Shunt) but these measures also frequently result in complications, which are often serious, and are thus performed hesitantly.
None of the existing devices are able to drain the peritoneal cavity except through temporary transabdominal insertion of a drainage catheter. These devices provide little improvement over the intermittent punctures of paracentesis and result in increased rates of infection if left in place for any length of time. The present invention will obviate the need for a long-term abdominal incision and, therefore, will eliminate the associated increased risk of serious infection.
The present invention relates to a device designed for implantation in the wall of the bladder that permits the drainage of excessive fluid into the bladder.
In one embodiment, this device includes a hollow, cylindrical column with flanges at both ends to provide secure anchorage in the bladder wall. Preferably there is a mechanism to provide unidirectional flow of fluid and prevent reflux of urine inside the column. A preferred embodiment of the device provides a passive ball-valve mechanism, which allows for drainage of fluid into the bladder whenever a certain pressure is achieved at the collection site. Another preferred embodiment of the device provides an active valve mechanism, which allows for controlled drainage of fluid into the bladder whenever the valve is actuated. The most preferred embodiment of the device includes a pump in addition to an active valve mechanism.
The present invention avoids the difficulties associated with the current therapies for chronic ascites, namely, the procedure allows the drainage of peritoneal fluid without (1) the serious complications of pharmaceuticals, (2) the inconvenience, the substantial costs and the increased risk of infection associated with frequent paracenteses, and (3) the multiple severe complications associated with more invasive and risky surgical operations to treat the cause of ascites.
When used to treat ascites, a device according to the present invention can be implanted either through a transurethral or transabdominal route. In order to drain other sites, the bladder component is implanted as above, and a flexible tube or other conduit may be incorporated to place the receptacle end of the device in a fashion tailored to the region to be drained. More specifically, such embodiment pertains to a peritoneo-vesicular drainage device permitting unidirectional flow of peritoneal fluid from the peritoneal cavity into the bladder.
In all embodiments, it is preferred that the device be constructed with biocompatible materials.
Methods of use of devices according to the present invention are also disclosed herein.
As can be seen in
The hollow shaft of the device contains a ball-valve 4 through which a positive closing pressure is provided by an attached spring 5.
The fluid collection interface of the device 1 may optionally include a large pore mesh 6 to allow for free flow of fluid while preventing incarceration of tissues at the drainage site.
As can be seen in
If the pressure of the bladder cavity 8 and the force of the spring 5, though, are greater than the pressure of the fluid collection (in this case the peritoneal cavity) 7, then the valve 4 will remain closed preventing reflux of urine 19 into the peritoneal cavity as depicted in
The device is designed to be placed transurethrally or transabdominally via an insertion device 10 such as that depicted in
Alternatively, the device may contain a length of tubing 11 or other means of fluid transport to reach the fluid collection as well as an optional perforated receptacle 12, 17 and 18 through which the fluid collection will drain into the tubing. Such other means of fluid transport include, but are not limited to, conduit, catheter, channel, lumen, hose, pipe, duct, artery or vessel. The device may contain one or more valves of a variety of types including passive valves 4, 13 (flapper-valve), 14 (in
The device is also designed to be able to incorporate a pump mechanism 16 as shown in
Alternatively, maneuvers which increase the pressure of the fluid cavity can also be utilized with the passive valves 4, 13, 14 to affect drainage such as bearing down to increase intraabdominal pressure to drain the peritoneal cavity or application of a girdle designed to increase abdominal pressure.
The device will be designed to drain a variety of different fluid collections including, but not limited to, the peritoneal cavity
Of particular interest to the inventors is the use of the invention to drain pulmonary effusions and other fluid collections in the lungs, in
While these are the preferred embodiments, the device could employ any mechanism which provides a unidirectional passive or active valve for the drainage of any body fluid into the urinary bladder. This could involve filtration of the fluid through a polymer so as to sequester albumin and other proteins in the fluid collection while allowing flow of water and ions across the semi-permeable membrane. This could also involve an electronic valve triggered via communication across the tissues of the human body through EMFs such as radio, electricity, pressure, mechanical, magnetism, or other means of communication, allowing drainage only at selected times.
The valve of the device can take many shapes and the device can be manufactured from any of a variety of materials with the only requirement being that of biocompatibility. Alternatively, the device, in either the active or passive embodiment, may incorporate anti-infective components in order to prevent the spread of infection between the body cavities. Such anti-infective components include, but are not limited to, bacteriostatic materials, bacteriocidal materials, one or more antibiotic dispensers, antibiotic eluting materials, entrained radioisotopes, a heating element, bioactive plastics, surfaces which encourage epithelialization, and coatings which prevent bacterial adhesion.
Alternatively, the device, in either the active or passive embodiment, may incorporate anti-clogging components. Such anti-clogging components include, but are not limited to, an active ultrasonic component, an inner and outer sleeve which, when actively agitated, disrupt the inner lumen, surfaces which encourage epithelialization, enzyme eluting materials, enzyme eluting materials which specifically target the proteinaceous components of ascites, chemical eluting surfaces, an intermittent plunger mechanism, and coatings which prevent adhesion of proteinaceous compounds.
While the device is primarily contemplated for use in human patients, the inventors also contemplate that the invention will have veterinary uses or product development purposes in equine, bovine, canine, feline, and other mammalian species.
Further, while the invention has been described in connection with the above described embodiments, it is not intended to limit the scope of the invention to the particular forms set forth, but on the contrary, it is intended to cover such alternatives, modifications, and equivalents as may be included within the scope of the invention. Still further, the scope of the present invention fully encompasses other embodiments that may become obvious to those skilled in the art and the scope of the present invention is limited only by the appended claims.
This application is a divisional application of U.S. application Ser. No. 10/369,550 filed on Feb. 21, 2003, which claims the priority of U.S. Provisional Application Ser. No. 60/359,287 filed on Feb. 25, 2002 and U.S. Provisional Application Ser. No. 60/389,346 filed on Jun. 18, 2002, the entireties of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3516410 | Hakim | Jun 1970 | A |
3540451 | Zeman | Nov 1970 | A |
3575158 | Summers | Apr 1971 | A |
3608088 | Dorman et al. | Sep 1971 | A |
3626950 | Schulte | Dec 1971 | A |
3642004 | Osthagen et al. | Feb 1972 | A |
3654932 | Newkirk et al. | Apr 1972 | A |
3810259 | Summers | May 1974 | A |
3910283 | Leveen | Oct 1975 | A |
4083786 | Tsuda et al. | Apr 1978 | A |
4261341 | Hakim et al. | Apr 1981 | A |
4368737 | Ash | Jan 1983 | A |
4416657 | Berglund | Nov 1983 | A |
4418693 | LeVeen et al. | Dec 1983 | A |
4557724 | Gregonis et al. | Dec 1985 | A |
4584994 | Bamberger et al. | Apr 1986 | A |
4595390 | Hakim et al. | Jun 1986 | A |
4610625 | Bunn | Sep 1986 | A |
4610658 | Buchwald et al. | Sep 1986 | A |
4615691 | Hakim et al. | Oct 1986 | A |
4618343 | Polaschegg | Oct 1986 | A |
4657530 | Buchwald et al. | Apr 1987 | A |
4725207 | Buchwald et al. | Feb 1988 | A |
4779614 | Moise | Oct 1988 | A |
4850955 | Newkirk | Jul 1989 | A |
4904236 | Redmond et al. | Feb 1990 | A |
4950232 | Ruzicka et al. | Aug 1990 | A |
4963129 | Rusch | Oct 1990 | A |
4991594 | Angelchik | Feb 1991 | A |
5021048 | Buckholtz | Jun 1991 | A |
5037385 | O'Byrne | Aug 1991 | A |
5071408 | Ahmed et al. | Dec 1991 | A |
5078688 | Lobodzinski et al. | Jan 1992 | A |
5147281 | Thornton et al. | Sep 1992 | A |
5167615 | East et al. | Dec 1992 | A |
5254084 | Geary | Oct 1993 | A |
5356386 | Goldberg et al. | Oct 1994 | A |
5360414 | Yarger | Nov 1994 | A |
5385541 | Kirsch et al. | Jan 1995 | A |
5387188 | Watson et al. | Feb 1995 | A |
5395350 | Summers | Mar 1995 | A |
5397354 | Wilk et al. | Mar 1995 | A |
5431637 | Okada et al. | Jul 1995 | A |
5472323 | Hirabayashi et al. | Dec 1995 | A |
5474683 | Bryant et al. | Dec 1995 | A |
5489276 | Jamshidi | Feb 1996 | A |
5520632 | Leveen et al. | May 1996 | A |
5575770 | Melsky et al. | Nov 1996 | A |
5637083 | Bertrand et al. | Jun 1997 | A |
5725506 | Freeman et al. | Mar 1998 | A |
5830172 | Leveen et al. | Nov 1998 | A |
5902336 | Mishkin | May 1999 | A |
5947911 | Wong et al. | Sep 1999 | A |
5980478 | Gorsuch et al. | Nov 1999 | A |
5980480 | Rubenstein et al. | Nov 1999 | A |
5989207 | Hughes | Nov 1999 | A |
6007511 | Prywes | Dec 1999 | A |
6017355 | Hessel et al. | Jan 2000 | A |
D420738 | Carter et al. | Feb 2000 | S |
6022333 | Kensey | Feb 2000 | A |
6027442 | Von Iderstein | Feb 2000 | A |
6132415 | Finch et al. | Oct 2000 | A |
6162238 | Kaplan et al. | Dec 2000 | A |
6162487 | Darouiche | Dec 2000 | A |
6193684 | Burbank et al. | Feb 2001 | B1 |
6254567 | Treu et al. | Jul 2001 | B1 |
6264625 | Rubenstein et al. | Jul 2001 | B1 |
6417750 | Sohn | Jul 2002 | B1 |
6436087 | Lewis et al. | Aug 2002 | B1 |
6533733 | Hylton et al. | Mar 2003 | B1 |
6648906 | Lasheras et al. | Nov 2003 | B2 |
6689085 | Rubenstein et al. | Feb 2004 | B1 |
6827682 | Bugge et al. | Dec 2004 | B2 |
6846168 | Davis | Jan 2005 | B2 |
6875192 | Saul et al. | Apr 2005 | B1 |
6887214 | Levin et al. | May 2005 | B1 |
6894456 | Tsukamoto et al. | May 2005 | B2 |
6905474 | Borgensen | Jun 2005 | B2 |
6926691 | Miethke | Aug 2005 | B2 |
6955655 | Burbank et al. | Oct 2005 | B2 |
7025739 | Saul | Apr 2006 | B2 |
7025742 | Rubenstein et al. | Apr 2006 | B2 |
7128735 | Weston | Oct 2006 | B2 |
7195608 | Burnett | Mar 2007 | B2 |
7311690 | Burnett | Dec 2007 | B2 |
7335179 | Burnett | Feb 2008 | B2 |
7419483 | Shehada | Sep 2008 | B2 |
20010025170 | Paderni | Sep 2001 | A1 |
20020013545 | Soltanpour et al. | Jan 2002 | A1 |
20020022793 | Bertrand et al. | Feb 2002 | A1 |
20020107467 | Levin | Aug 2002 | A1 |
20040049288 | Levin | Mar 2004 | A1 |
20050096582 | Burnett | May 2005 | A1 |
20050131340 | Sorenson et al. | Jun 2005 | A1 |
20050273034 | Burnett | Dec 2005 | A1 |
20060036208 | Burnett | Feb 2006 | A1 |
20060058731 | Burnett et al. | Mar 2006 | A1 |
20070106205 | Connell et al. | May 2007 | A1 |
20080108935 | Nyhart, Jr. | May 2008 | A1 |
Number | Date | Country |
---|---|---|
2 350 794 | Dec 2000 | GB |
WO 9741799 | Nov 1997 | WO |
WO 9816171 | Apr 1998 | WO |
Entry |
---|
Rozenblit, Grigory N., Peritoneal-Urinary Drainage for Treatment of Refractory Ascites: A Pilot Study, Journal of Vascular & Interventional Radiology, Nov./Dec. 1998, 9(6):998-1005, NY. |
U.S. Appl. No. 11/933,214, filed Oct. 31, 2007, Burnett. |
Costanzo et al., “Early Ultrafiltration in Patients with Decompensated Heart Failure and Diuretic Resistance,” J. Am. Coll. Cardiol., vol. 46 (11), pp. 2047-2051 (2005). |
Fioulberg et al., “Terminal Right Heart Failure Due to Complex Congenital Cardiac Disease Successfully Managed by Ilome Peritoneal Drainage,” Cardiol. Young, vol. 13, pp. 568-570 (2003). |
Ortiz et al., “Long-Term Automated Peritoneal Dialysis in Patients with Refractory Congestive Heart Failure,” Advances in Peritoneal Dialysis, vol. 19, pp. 77-80 (2003). |
International Search Report for PCT/US03/05145, 3 pages (mailed Jul. 17, 2003). |
USPTO, Supplemental Notice of Allowability for U.S. Appl. No. 10/369,550, 2 pages (mailed Dec. 17, 2007). |
USPTO, Notice of Allowance and Fees Due for U.S. Appl. No. 10/369,550, 4 pages (mailed Sep. 24, 2007). |
USPTO, Non-Final Office Action for U.S. Appl. No. 10/369,550, 13 pages (mailed Mar. 09, 2006). |
USPTO, Corrected Notice of Allowance and Fees Due for U.S. Appl. No. 10/700,863, 5 pages (mailed Nov. 08, 2007). |
USPTO, Notice of Allowance and Fees Due for U.S. Appl. No. 10/700.863, 7 pages (mailed Nov. 2, 2006). |
USPTO, Non-Final Office Action for U.S. Appl. No. 10/700,863, 11 pages (mailed Feb. 2, 2006). |
USPTO, Supplemental Notice of Allowability for U.S. Appl. No. 11/198,079, 2 pages (mailed Jan. 9, 2007). |
USPTO, Notice of Allowance and Fees Due for U.S. Appl. No. 11/198,079, 4 pages (mailed Oct. 5, 2006). |
USPTO, Non-Final Office Action for U.S. Appl. No. 11/198,079, 7 pages (mailed Feb. 2, 2006). |
USPTO, Non-Final Office Action for U.S. Appl. No. 11/181,539, 10 pages (mailed Sep. 16, 2008). |
USPTO, Final Office Action for U.S. Appl. No. 11/181,539, 10 pages. (mailed Mar. 18, 2008). |
USPTO, Non-Final Office Action for U.S. Appl. No. 11/181,539, 8 pages (mailed May 22, 2007). |
USPTO, Final Office Action for U.S. Appl. No. 11/181,539, 6 pages (mailed Oct. 10, 2006). |
USPTO, Non-Final Office Action for U.S. Appl. No. 11/181,539, 8 pages (mailed Jan. 7, 2006). |
USPTO, Final Office Action for U.S. Appl. No. 10/826,237, 10 pages (mailed Oct. 28, 2008). |
USPTO, Non-Final Office Action for U.S. Appl. No. 10/826,237, 10 pages (mailed Feb. 22, 2008). |
USPTO, Final Office Action for U.S. Appl. No. 10/826,237, 10 pages (mailed Jul. 5, 2007). |
USPTO, Non-Final Office Action for U.S. Appl. No. 10/826,237, 8 pages (mailed Dec. 19, 2006). |
USPTO, Office Action mailed Dec. 19, 2006, U.S. Appl. No. 10/826,237. |
USPTO, Final Office Action mailed Jul. 05, 2007, U.S. Appl. No. 10/826,237. |
USPTO, Advisory Action mailed Nov. 20, 2007, U.S. Appl. No. 10/826,237. |
USPTO, Office Action mailed Feb. 22, 2008, U.S. Appl. No. 10/826,237. |
USPTO, Final Office Action mailed Oct. 28, 2008, U.S. Appl. No. 10/826,237. |
USPTO, Office Action mailed Apr. 13, 2009, U.S. Appl. No. 10/826,237. |
USPTO, Office Action mailed Jan. 27, 2006, U.S. App. No. 11/181,539. |
USPTO, Final Office Action mailed Oct. 10, 2006, U.S. Appl. No. 11/181,539. |
USPTO, Office Action mailed May 22, 2007, U.S. Appl. No. 11/181,539. |
USPTO, Final Office Action mailed Mar. 18, 2007, U.S. Appl. No. 11/181,539. |
USPTO, Office Action mailed Sep. 16, 2008, U.S. Appl. No. 11/181,539. |
USPTO, Notice of Allowance with reasons for allowance mailed Jul. 20, 2009, U.S. Appl. No. 11/181,539. |
USPTO, Final Office Action mailed Dec. 13, 2006, U.S. Appl. No. 10/369,550, 4 pages. |
USPTO, Non-Final Office Action mailed Mar. 9, 2006, U.S. Appl. No. 10/369,550, 13 pages. |
USPTO, Notice of Allowance with reasons for allowance mailed Jul. 20, 2009, U.S. Appl. No. 11/181,539, 9 pages. |
USPTO, Advisory Action mailed Jul. 14, 2008, U.S. Appl. No. 11/181,539, 3 pages. |
USPTO, Non-Final Office Action mailed Jan. 27, 2006, U.S. Appl. No. 11/181,539, 8 pages. |
USPTO, Final Office Action mailed Jan. 05, 2010, U.S. Appl. No. 10/826,237, 13 pages. |
USPTO, Advisory Action mailed Nov. 20, 2007, U.S. Appl. No. 10/826,237, 3 pages. |
USPTO, Non-Final Office Action mailed Apr. 6, 2010, U.S. Appl. No. 11/933,214, 18 pages. |
Number | Date | Country | |
---|---|---|---|
20080154173 A1 | Jun 2008 | US |
Number | Date | Country | |
---|---|---|---|
60359287 | Feb 2002 | US | |
60389346 | Jun 2002 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10369550 | Feb 2003 | US |
Child | 12014696 | US |